Amgen, Servier sign licensing deal for cardiovascular drug

07/10/2013 | American City Business Journals · Drug Store News

Servier granted Amgen rights to market its heart failure and angina drug Procoralan, or ivabradine, in the U.S. as well as an exclusive option to develop and market its experimental heart failure drug S38844. Servier could get $50 million upfront plus milestone fees and sales royalties for ivabradine, which is already cleared in Europe. The deal also gives Servier rights to commercialize Amgen's heart failure drug candidate omecamtiv mecarbil in Europe.

View Full Article in:

American City Business Journals · Drug Store News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
White Plains, NY
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ